- Home
- FHTX vs FCT Comparison
FHTX vs FCT Comparison
Compare FHTX & FCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- FCT
- Stock Information
- Founded
- FHTX 2015
- FCT 2004
- Country
- FHTX United States
- FCT United States
- Employees
- FHTX N/A
- FCT N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- FCT Finance Companies
- Sector
- FHTX Health Care
- FCT Finance
- Exchange
- FHTX Nasdaq
- FCT Nasdaq
- Market Cap
- FHTX 278.1M
- FCT 251.8M
- IPO Year
- FHTX 2020
- FCT N/A
- Fundamental
- Price
- FHTX $4.23
- FCT $9.70
- Analyst Decision
- FHTX Strong Buy
- FCT
- Analyst Count
- FHTX 5
- FCT 0
- Target Price
- FHTX $11.80
- FCT N/A
- AVG Volume (30 Days)
- FHTX 270.7K
- FCT 106.8K
- Earning Date
- FHTX 10-31-2025
- FCT 01-01-0001
- Dividend Yield
- FHTX N/A
- FCT 11.29%
- EPS Growth
- FHTX N/A
- FCT N/A
- EPS
- FHTX N/A
- FCT N/A
- Revenue
- FHTX $24,173,000.00
- FCT N/A
- Revenue This Year
- FHTX $42.43
- FCT N/A
- Revenue Next Year
- FHTX $14.77
- FCT N/A
- P/E Ratio
- FHTX N/A
- FCT N/A
- Revenue Growth
- FHTX N/A
- FCT N/A
- 52 Week Low
- FHTX $2.95
- FCT $9.45
- 52 Week High
- FHTX $9.70
- FCT $10.42
- Technical
- Relative Strength Index (RSI)
- FHTX 45.28
- FCT 39.48
- Support Level
- FHTX $3.85
- FCT $9.61
- Resistance Level
- FHTX $4.69
- FCT $9.79
- Average True Range (ATR)
- FHTX 0.33
- FCT 0.09
- MACD
- FHTX 0.04
- FCT 0.00
- Stochastic Oscillator
- FHTX 55.77
- FCT 32.35
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.